Highlights Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Real-time Estimate Cboe BZX Other stock markets 09:58:31 2024-05-10 EDT			5-day change	1st Jan Change
42.36 ^USD	-0.39%		-11.37%	-29.73%

05-09	Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing	MT
05-08	UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises	05-07	MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q1 Revenue $172.3M	05-07	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	04-26	MT
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	04-26	CI
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	02-27	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q4 Revenue $146.4M	02-27	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application	01-26	CI
Apellis says EU regulator panel may not back its eye disease drug	12-14	RE
Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union	12-14	CI
Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI	12-11	CI
Apellis Pharmaceuticals Shares Rise on Updates for US Prescribing Information for Syfovre	12-01	MT
Apellis Pharmaceuticals Q3 Loss Narrows, Revenue Rises	11-01	MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q3 Revenue $110.4M	11-01	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
Apellis Pharmaceuticals, Inc. Announces the Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE®? (pegcetacoplan Injection) for Geographic Atrophy (GA)	23-10-20	CI
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G	23-10-17	CI
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week	23-10-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Highlights

Filters